USPH

Analyst Note: U.S. Physical Therapy, Inc. (USPH)

Date: June 20, 2026 Current Price: $63.32

1. Structural Readiness

• Conservative Entry: Pending confirmed close above the resistance level (breakout level).
• Breakout Level: Not yet defined in the text; requires price action to establish the resistance ceiling of the coil.
• Current Price: $63.32.
• Extension: Not applicable (price is within the consolidation range, not extended above the breakout).
• ATR Context: Current ATR is 4.0% (High). This falls within the historical "sweet spot" (4–6%) for structural quality, suggesting sufficient volatility to support a move without the extreme risk associated with >8% ATR.

2. Thesis Layer

• Thesis Classification: Tactical, Setup-Led.
• Macro Thesis: There is no named secular thesis attached to this specific setup as of June 20, 2026. The investment case is not driven by a broad macro narrative (e.g., "Silver Bullet" or "Secular Growth") but is strictly a function of the structural setup quality combined with the company's fundamental execution.
• Judgment Criteria: The conviction must be derived entirely from the quality of the "Growth Leader" archetype, the strength of the forming coil, and the tangible business fundamentals reported in the Q1 2026 earnings and subsequent filings. No external macro assumptions should be injected.

3. Business Overview

U.S. Physical Therapy, Inc. operates as a leading provider of outpatient rehabilitation services in the United States. The company operates through two primary segments:

• Physical Therapy Operations: Provides physical therapy, speech therapy, and occupational therapy clinics and home-care practices. These services treat orthopedic disorders, sports injuries, and injured workers.
• *Scale:* As of December 31, 2025, the company owned or managed 780 clinics across 44 states (Evidence E19).
• *Volume:* First Quarter 2026 saw 1.543 million patient visits, a 6.9% increase year-over-year (Evidence E4).
• *Revenue Quality:* Net patient revenue per visit was $106.49 in Q1 2026 (Evidence E6).
• *Payer Mix:* Commercial payers represent nearly 50% of the total payer mix (Evidence E5).
• Industrial Injury Prevention (IIP): Provides onsite injury prevention, rehabilitation, performance optimization, and occupational medicine testing.
• *Revenue:* IIP revenue was $31 million in Q1 2026, up 11.8% year-over-year (Evidence E8).
• *Clients:* The majority of IIP revenue is contracted directly with employers, including Fortune 500 companies (Evidence E11).

Recent Strategic Activity (as of Q1 2026):

• Acquisitions: The company acquired a 50% interest in an eight-clinic practice (8 clinics, $8M revenue, 60k visits) in January 2026 (Evidence E7, E13). It also acquired a 70% interest in an IIP business in January 2026 (Evidence E14).
• Financing: On April 14, 2026, the company closed a $450 million, five-year credit facility (comprising a $175M term loan and $275M revolver) with a maturity date of April 14, 2031 (Evidence E15).
• Operational Transition: The company initiated a transition process for NYU clinics, expecting to be materially complete by the end of Q3 2026, with full quarterly run-rate impact expected in Q4 2026 (Evidence E2, E3).
• Guidance: Management reaffirmed full-year 2026 adjusted EBITDA guidance of $102 million to $106 million (Evidence E1).
• Reimbursement Environment: For 2026, the Medicare Physician Fee Schedule (MPFS) increased reimbursement for therapy services by approximately 1.75% compared to 2025 (Evidence E16, E24).

4. Archetype and Conviction Analysis

• Archetype: Growth Leader.
• *Fit:* The company demonstrates consistent top-line growth (6.9% visit growth, 11.8% IIP growth), active M&A execution (multiple acquisitions in 2026), and a clear path to margin expansion via the NYU transition and acquired synergies. The "Growth Leader" archetype is supported by the "margin inflector" dynamic of the NYU transition, which management expects to add a $7 million run-rate impact by Q4 2026.
• Valuation & Fundamentals:
• The company is trading at a price that reflects its growth trajectory. The reaffirmed EBITDA guidance of $102M–$106M provides a clear financial spine.
• The ATR of 4.0% indicates a healthy volatility profile, neither too stagnant nor too erratic, supporting the "Growth Leader" classification.
• Conviction Stack:
• *Thesis Strength:* Moderate (Tactical/Setup-led, no macro tailwinds).
• *Evidence Quality:* High. Multiple primary sources (earnings transcripts, 10-Q/10-K filings) confirm growth, guidance, and strategic moves.
• *Rerating Potential:* Dependent on the successful execution of the NYU transition and the realization of the $7M run-rate impact in Q4.

5. Invalidation, Strengthening, and Gaps

• Strengthening: A confirmed breakout above the resistance level (conservative entry) would confirm the setup. Fundamentally, evidence of the NYU transition completing ahead of schedule or IIP revenue growth accelerating beyond 11.8% would strengthen the conviction.
• Gaps in Evidence:
• Breakout Level: The specific resistance level required for a confirmed breakout is not quantified in the text.
• Q2 2026 Data: As of June 20, 2026, Q2 2026 results are not yet reported; the most recent data is Q1 2026.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Reaffirmed full-year 2026 EBITDA guidance of $102M-$106M; 6.9% YoY growth in patient visits to 1.543M in Q1 2026; successful execution of $450M credit facility refinancing in April 2026; NYU transition expected to add $7M run-rate impact by Q4 2026. Key risks: Execution risk on NYU transition timeline; potential for Medicare reimbursement rates to change unexpectedly despite 1.75% increase; integration risk from recent M&A activity; lack of a named secular macro thesis to support multiple expansion. Sizing hint: Position size should reflect the "forming" status of the coil; allocate based on the probability of breakout rather than confirmed momentum. Expected path: Management expects the NYU transition to complete in Q3 2026, leading to full run-rate impact in Q4 2026; price likely to consolidate near current levels until a confirmed breakout occurs. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation).